A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

被引：0
作者：
Ngu, Siew-Fei [1 ]
Ngan, Hextan Y. S. [1 ]
Chan, Karen K. L. [1 ]
机构：
[1] Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Peoples R China
来源：
CANCER DRUG RESISTANCE | 2022年 / 5卷 / 03期
关键词：
Ovarian cancer; PARP inhibitor; BRCA; RAD51C; HOMOLOGOUS RECOMBINATION GENES; GERMLINE BRCA1/2 MUTATION; OLAPARIB MONOTHERAPY; CANCER;
D O I：
10.20517/cdr.2022.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression.
引用
收藏
页码：662 / 666
页数：5
相关论文
共 12 条
  • [1] [Anonymous], Clinical Practice Guidelines in Oncology, Inc
  • [2] Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation
    Chandran, Elias A.
    Kennedy, Ian
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 4
  • [3] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    Colombo, N.
    Sessa, C.
    du Bois, A.
    Ledermann, J.
    McCluggage, W. G.
    McNeish, I.
    Morice, P.
    Pignata, S.
    Ray-Coquard, I.
    Vergote, I.
    Baert, T.
    Belaroussi, I.
    Dashora, A.
    Olbrecht, S.
    Planchamp, F.
    Querleu, D.
    Banerjee, S.
    Blecharz, P.
    Bruchim, I.
    Cibula, D.
    Concin, N.
    Davidson, B.
    Devouassoux-Shisheboran, M.
    Ferrero, A.
    Glasspool, R.
    Gonzalez-Martin, A.
    Heinzelmann-Schwarz, V.
    Joly, F.
    Kim, J. W.
    Kridelka, F.
    Lorusso, D.
    Mahner, S.
    Mikami, M.
    Mirza, M. R.
    Nicum, S.
    O'Donnell, D. M.
    Pautier, P.
    Rodolakis, A.
    Sehouli, J.
    Selcukbiricik, F.
    Singh, N.
    Tan, D. S. P.
    Timmerman, D.
    Tognon, G.
    van der Velden, J.
    Witteveen, P. O.
    Zeimet, A. G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) : 728 - 760
  • [4] Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
    Domchek, Susan M.
    Aghajanian, Carol
    Shapira-Frommer, Ronnie
    Schmutzler, Rita K.
    Audeh, M. William
    Friedlander, Michael
    Balmana, Judith
    Mitchell, Gillian
    Fried, Georgeta
    Stemmer, Salomon M.
    Hubert, Ayala
    Rosengarten, Ora
    Loman, Niklas
    Robertson, Jane D.
    Mann, Helen
    Kaufman, Bella
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 199 - 203
  • [5] Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
    Matulonis, U. A.
    Penson, R. T.
    Domchek, S. M.
    Kaufman, B.
    Shapira-Frommer, R.
    Audeh, M. W.
    Kaye, S.
    Molife, L. R.
    Gelmon, K. A.
    Robertson, J. D.
    Mann, H.
    Ho, T. W.
    Coleman, R. L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (06) : 1013 - 1019
  • [6] Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
    Norquist, Barbara M.
    Brady, Mark F.
    Harrell, Maria I.
    Walsh, Tom
    Lee, Ming K.
    Gulsuner, Suleyman
    Bernards, Sarah S.
    Casadei, Silvia
    Burger, Robert A.
    Tewari, Krishnansu S.
    Backes, Floor
    Mannel, Robert S.
    Glaser, Gretchen
    Bailey, Cheryl
    Rubin, Stephen
    Soper, John
    Lankes, Heather A.
    Ramirez, Nilsa C.
    King, Mary Claire
    Birrer, Michael J.
    Swisher, Elizabeth M.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (04) : 777 - 783
  • [7] Inherited Mutations in Women With Ovarian Carcinoma
    Norquist, Barbara M.
    Harrell, Maria I.
    Brady, Mark F.
    Walsh, Tom
    Lee, Ming K.
    Gulsuner, Suleyman
    Bernards, Sarah S.
    Casadei, Silvia
    Yi, Qian
    Burger, Robert A.
    Chan, John K.
    Davidson, Susan A.
    Mannel, Robert S.
    DiSilvestro, Paul A.
    Lankes, Heather A.
    Ramirez, Nilsa C.
    King, Mary Claire
    Swisher, Elizabeth M.
    Birrer, Michael J.
    [J]. JAMA ONCOLOGY, 2016, 2 (04) : 482 - 490
  • [8] Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
    Pennington, Kathryn P.
    Walsh, Tom
    Harrell, Maria I.
    Lee, Ming K.
    Pennil, Christopher C.
    Rendi, Mara H.
    Thornton, Anne
    Norquist, Barbara M.
    Casadei, Silvia
    Nord, Alexander S.
    Agnew, Kathy J.
    Pritchard, Colin C.
    Scroggins, Sheena
    Garcia, Rochelle L.
    King, Mary-Claire
    Swisher, Elizabeth M.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (03) : 764 - 775
  • [9] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
    Pujade-Lauraine, Eric
    Ledermann, Jonathan A.
    Selle, Frederic
    Gebski, Val
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Poveda, Andres
    Pignata, Sandro
    Friedlander, Michael
    Colombo, Nicoletta
    Harter, Philipp
    Fujiwara, Keiichi
    Ray-Coquard, Isabelle
    Banerjee, Susana
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Pautier, Patricia
    [J]. LANCET ONCOLOGY, 2017, 18 (09) : 1274 - 1284
  • [10] Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population
    Song, Honglin
    Dicks, Ed
    Ramus, Susan J.
    Tyrer, Jonathan P.
    Intermaggio, Maria P.
    Hayward, Jane
    Edlund, Christopher K.
    Conti, David
    Harrington, Patricia
    Fraser, Lindsay
    Philpott, Susan
    Anderson, Christopher
    Rosenthal, Adam
    Gentry-Maharaj, Aleksandra
    Bowtell, David D.
    Alsop, Kathryn
    Cicek, Mine S.
    Cunningham, Julie M.
    Fridley, Brooke L.
    Alsop, Jennifer
    Jimenez-Linan, Mercedes
    Hogdall, Estrid
    Hogdall, Claus K.
    Jensen, Allan
    Kjaer, Susanne Krueger
    Lubinski, Jan
    Huzarski, Tomasz
    Jakubowska, Anna
    Gronwald, Jacek
    Poblete, Samantha
    Lele, Shashi
    Sucheston-Campbell, Lara
    Moysich, Kirsten B.
    Odunsi, Kunle
    Goode, Ellen L.
    Menon, Usha
    Jacobs, Ian J.
    Gayther, Simon A.
    Pharoah, Paul D. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) : 2901 - +
12